Using ctDNA as an endpoint in your cancer clinical trial? FDA wants to hear from you

Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies

The Friends of Cancer Research annual meeting, to be held Nov. 4 in Washington, DC, will focus on three questions facing the field of oncology clinical trial design.

Early endpoints are a balance of risk and benefit

Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.

October 29, 2025

Vol.51 No.39

Regulatory News

Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC
ctMoniTR project aims to improve efficiency in development of intermediate endpoints

New research led by Friends of Cancer Research demonstrates that decreases in circulating tumor DNA after initiation of treatment are associated with improved overall survival in patients with advanced non-small cell lung cancer treated with immunotherapy or chemotherapy.

October 24, 2025

Vol.51 No.39

By Jacquelyn Cobb

Why both somatic and germline genomic profiling are essential for precision oncology

Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations.

October 17, 2025

Vol.51 No.38

By Heather Hampel and David W. Craig

In Brief

Monica Bertagnolli joins Friends of Cancer Research board of directors

Monica Bertagnolli, former director of NIH and NCI, joined the Friends of Cancer Research as board of directors.

March 07, 2025

Vol.51 No.09

Drugs & Targets

FDA grants de novo authorization for PGDx elio plasma focus Dx, a kitted, pan-solid tumor liquid biopsy test

Labcorp announced it has received de novo marketing authorization from FDA for PGDx elio plasma focus Dx—the industry’s first and only kitted, pan-solid tumor liquid biopsy test.

August 09, 2024

Vol.50 No.32

Using ctDNA as an endpoint in your cancer clinical trial? FDA wants to hear from you

YOU MAY BE INTERESTED IN

Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies

Early endpoints are a balance of risk and benefit

Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC
ctMoniTR project aims to improve efficiency in development of intermediate endpoints

Why both somatic and germline genomic profiling are essential for precision oncology

Monica Bertagnolli joins Friends of Cancer Research board of directors

FDA grants de novo authorization for PGDx elio plasma focus Dx, a kitted, pan-solid tumor liquid biopsy test

Renew today!

Subscriber content

Never miss an issue!

Login

Using ctDNA as an endpoint in your cancer clinical trial? FDA wants to hear from you

YOU MAY BE INTERESTED IN

Friends publishes three white papers ahead of annual meetingTopics: Clinical trials on rare cancers, combination drug trials, multi-regional studies

Early endpoints are a balance of risk and benefit

Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLCctMoniTR project aims to improve efficiency in development of intermediate endpoints

Why both somatic and germline genomic profiling are essential for precision oncology

Monica Bertagnolli joins Friends of Cancer Research board of directors

FDA grants de novo authorization for PGDx elio plasma focus Dx, a kitted, pan-solid tumor liquid biopsy test

Never miss an issue!

Login

Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies

Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC
ctMoniTR project aims to improve efficiency in development of intermediate endpoints